Wave Life Sciences, Inc. (WVE)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
3.09 USD
-0.05
(-1.592%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 3.13 +0.04 (1.295%) ⇧ (Oct. 14, 2026, 5:38 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 4:13 a.m. EDT
The investment case for Wave Life Sciences is currently nonexistent due to a catastrophic collapse in business fundamentals. The company is hemorrhaging cash with negative free cash flow exceeding $128 million annually and has suffered a staggering 76% decline in share price over the last nine years. Recent earnings reports confirm a dire reality: revenue has plummeted by nearly 74% year-over-year, and gross margins are deeply negative, indicating the core business model is failing to generate value. Despite a 'strong buy' recommendation from analysts based on a theoretical target price of $18, this ignores the harsh reality that the company is burning through its remaining cash reserves without a viable path to profitability. The balance sheet, while currently showing low debt, is propped up by minimal cash and is unsustainable given the operational losses. There is no dividend to provide income, and the stock is trading at a premium to sales despite generating no profit. The overwhelming options activity confirms that the market is pricing in further deterioration rather than a turnaround. This is a value trap where the low price reflects a broken business, not a bargain opportunity. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.171577 |
| MSTL | 0.177355 |
| AutoETS | 0.181106 |
| AutoARIMA | 0.181107 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 17.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.330 |
| Excess Kurtosis | -0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.611 |
| Revenue per Share | 0.348 |
| Market Cap | 608,878,848 |
| Forward P/E | -2.66 |
| Beta | -1.43 |
| Previous Name | Wave Life Sciences Ltd. |
| Website | https://wavelifesciences.com |
As of Oct. 10, 2026, 4:13 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, evidenced by massive open interest in out-of-the-money puts relative to calls across all expirations. While there is some volume in calls targeting the $7-$10 range, the put/call ratio is heavily skewed toward hedging or betting on further declines, with significant concentration in strikes just above the current price.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6010165 |
| Address1 | 733 Concord Avenue |
| All Time High | 56.0 |
| All Time Low | 1.16 |
| Ask | 7.5 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 3,413,800 |
| Average Daily Volume3 Month | 3,145,930 |
| Average Volume | 3,145,930 |
| Average Volume10Days | 3,413,800 |
| Beta | -1.428 |
| Bid | 4.27 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 2.346 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.09 |
| Current Ratio | 9.987 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.13 |
| Day Low | 3.0399 |
| Debt To Equity | 9.611 |
| Display Name | Wave Life Sciences |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,414,600 |
| Earnings Call Timestamp Start | 1,785,414,600 |
| Earnings Timestamp | 1,785,414,600 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -214,520,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.755 |
| Enterprise To Revenue | 2.476 |
| Enterprise Value | 161,866,864 |
| Eps Current Year | -1.10149 |
| Eps Forward | -1.1612 |
| Eps Trailing Twelve Months | -1.06 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.6384 |
| Fifty Day Average Change | -1.5484002 |
| Fifty Day Average Change Percent | -0.33382204 |
| Fifty Two Week Change Percent | -60.101654 |
| Fifty Two Week High | 21.73 |
| Fifty Two Week High Change | -18.64 |
| Fifty Two Week High Change Percent | -0.85780025 |
| Fifty Two Week Low | 3.0399 |
| Fifty Two Week Low Change | 0.05009985 |
| Fifty Two Week Low Change Percent | 0.016480755 |
| Fifty Two Week Range | 3.0399 - 21.73 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,447,252,200,000 |
| Float Shares | 94,295,434 |
| Forward Eps | -1.1612 |
| Forward P E | -2.66104 |
| Free Cashflow | -128,778,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 317 |
| Fullday Change | -0.00999999 |
| Fullday Change Percent | -0.318471 |
| Fullday Price | 3.09 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -2.02001 |
| Gross Profits | -132,050,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15538 |
| Held Percent Institutions | 0.85322 |
| Implied Shares Outstanding | 197,048,175 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Wave Life Sciences, Inc. |
| Market | us_market |
| Market Cap | 608,878,848 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_256557334 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-15 |
| Net Income To Common | -202,472,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 778,340,291 |
| Number Of Analyst Opinions | 18 |
| Open | 3.09 |
| Operating Cashflow | -191,576,992 |
| Operating Margins | -32.48327 |
| Overall Risk | 5 |
| Phone | 617 949 2900 |
| Post Market Change | 0.0400002 |
| Post Market Change Percent | 1.2945049 |
| Post Market Price | 3.13 |
| Post Market Time | 1,792,013,895 |
| Prev Name | Wave Life Sciences Ltd. |
| Previous Close | 3.14 |
| Price Eps Current Year | -2.805291 |
| Price Hint | 4 |
| Price To Book | 1.3171356 |
| Price To Sales Trailing12 Months | 9.314204 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.672 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.31579 |
| Region | US |
| Regular Market Change | -0.0500002 |
| Regular Market Change Percent | -1.59236 |
| Regular Market Day High | 3.13 |
| Regular Market Day Low | 3.0399 |
| Regular Market Day Range | 3.0399 - 3.13 |
| Regular Market Open | 3.09 |
| Regular Market Previous Close | 3.14 |
| Regular Market Price | 3.09 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 2,824,903 |
| Return On Assets | -0.33601 |
| Return On Equity | -0.67417 |
| Revenue Growth | -0.739 |
| Revenue Per Share | 0.348 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 197,048,175 |
| Shares Percent Shares Out | 0.0942 |
| Shares Short | 18,556,315 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 16,281,873 |
| Short Name | Wave Life Sciences, Inc. |
| Short Percent Of Float | 0.1162 |
| Short Ratio | 5.45 |
| Source Interval | 15 |
| State | MA |
| Symbol | WVE |
| Target High Price | 42.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 18.05556 |
| Target Median Price | 14.5 |
| Total Cash | 490,601,984 |
| Total Cash Per Share | 2.49 |
| Total Debt | 43,590,000 |
| Total Revenue | 65,371,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.2202 |
| Two Hundred Day Average Change | -5.1301994 |
| Two Hundred Day Average Change Percent | -0.6240967 |
| Type Disp | Equity |
| Volume | 2,824,903 |
| Website | https://wavelifesciences.com |
| Zip | 2,138 |